Robust strategies in nuclear-targeted cancer therapy based on functional nanomaterials

dc.contributor.authorQin Xiaofei
dc.contributor.authorZhang Hanyi
dc.contributor.authorXing Xin
dc.contributor.authorWang Peng
dc.contributor.authorYan Jiaqi
dc.contributor.authorLiu Daishun
dc.contributor.authorGong Qiuyu
dc.contributor.authorZhang Renshuai
dc.contributor.authorZhang Hongbo
dc.contributor.organizationfi=Turun biotiedekeskus|en=Turku Bioscience Centre|
dc.contributor.organization-code1.2.246.10.2458963.20.18586209670
dc.converis.publication-id176222948
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/176222948
dc.date.accessioned2022-11-29T15:53:23Z
dc.date.available2022-11-29T15:53:23Z
dc.description.abstractNucleus, as the machinery for genome transcription, play prominent roles to support the fundamental cel-lular functions, the destruction of any of these specific parts would significantly modulate the cell function. Therefore, troumendous drug delivery systems with enhanced nucleus targeting ability have been studied for nucleus-related disease regulation. The purpose of this review is to sort out the fundamental nuclear tar-geting strategy, especially the active mechanism of various nuclear targeting ligands and their extensive applications based on cancer targeting therapy. Various nuclear targeting ligands are first introduced to understand their nuclear entry mechanism. Next, to overcome biological barriers and avoid the serum pro-tein absorption, diverse robust delivery strategies based on different nuclear targeting ligands are dis-cussed. Moreover, other sophisticated carrier systems with enhanced nuclear entry, while without nuclear targeting ligands are also assembled. At the end the challenges and future opportunities in the field of nuclear targeting nanotherapeutics are tentatively proposed, to speed up their clinical translation. (c) 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).
dc.identifier.eissn0264-1275
dc.identifier.jour-issn0264-1275
dc.identifier.olddbid190310
dc.identifier.oldhandle10024/173401
dc.identifier.urihttps://www.utupub.fi/handle/11111/34994
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0264127522006219
dc.identifier.urnURN:NBN:fi-fe2022091258803
dc.language.isoen
dc.okm.affiliatedauthorZhang, Hongbo
dc.okm.discipline3122 Cancersen_GB
dc.okm.discipline3122 Syöpätauditfi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA2 Scientific Article
dc.publisherELSEVIER SCI LTD
dc.publisher.countryUnited Kingdomen_GB
dc.publisher.countryBritanniafi_FI
dc.publisher.country-codeGB
dc.relation.articlenumber110999
dc.relation.doi10.1016/j.matdes.2022.110999
dc.relation.ispartofjournalMaterials and Design
dc.relation.volume221
dc.source.identifierhttps://www.utupub.fi/handle/10024/173401
dc.titleRobust strategies in nuclear-targeted cancer therapy based on functional nanomaterials
dc.year.issued2022

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
1-s2.0-S0264127522006219-main.pdf
Size:
5.41 MB
Format:
Adobe Portable Document Format